Focused On-demand Library for Translation initiation factor eIF-2B subunit alpha

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14232

UPID:

EI2BA_HUMAN

Alternative names:

eIF-2B GDP-GTP exchange factor subunit alpha

Alternative UPACC:

Q14232; A6NLY9; B4DGX0; Q3SXP4

Background:

Translation initiation factor eIF-2B subunit alpha, also known as eIF-2B GDP-GTP exchange factor subunit alpha, plays a pivotal role in protein synthesis. It catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP, a critical step in the initiation of protein translation. This protein's function underscores its importance in cellular biology and its potential impact on understanding disease mechanisms.

Therapeutic significance:

Leukoencephalopathy with vanishing white matter 1, a devastating brain disease, is directly linked to mutations affecting this protein. The disease's progression and its impact on neurological functions highlight the critical role of eIF-2B subunit alpha in brain health. Understanding the role of Translation initiation factor eIF-2B subunit alpha could open doors to potential therapeutic strategies for this and related neurological disorders.